| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2005 | US20050037010 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 02/17/2005 | US20050037007 In a tissue, organ or wound site using a synergistic mixture of transforming growth factor beta inhibitors and agents that degrade the excess accumulated extracellular matrix; fibrotic diseases and scarring |
| 02/17/2005 | US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents |
| 02/17/2005 | US20050036998 Mixture with a thixotropic gelatine carrier to form gelatin capsules; enhanced the solubility, stability and absorption |
| 02/17/2005 | US20050036997 Molecular modeling of the binding sites for anisomycin, azithromycin, erythromycin, linezolid, tylosin, carbomycin A, spiramycin, virginiamycin, sparsomycin and blasticidin using the Haloarcular marismortui large ribosomal subunit; drug design and drug screening |
| 02/17/2005 | US20050036995 Immunogens; tumor antigens; kits |
| 02/17/2005 | US20050036993 Immune activation by double-stranded polynucleotides |
| 02/17/2005 | US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/17/2005 | US20050036983 In vivo use of water absorbent polymers |
| 02/17/2005 | US20050036981 Pyridoxal 5' phosphate (PLP) dependent enzymes, recombinant methioninase (rMETase), extend serum half-life, extend in vivo period of methionine depletion in host, and decrease immunogenicity; cancer |
| 02/17/2005 | US20050036978 Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| 02/17/2005 | US20050036977 Water insoluble substance complexed with ion exchange resin; rapid-disintegrating tablet/film; effervescence |
| 02/17/2005 | US20050036963 Compositions and methods for treating skin conditions |
| 02/17/2005 | US20050036962 Compositions and method for protecting skin from UV induced immunosuppression and skin damage |
| 02/17/2005 | US20050036954 a toothpaste, a sexual enhancement chemical compound such as sildenafil citrate, vardenafil hydrochloride or tadalafil and medicinal herbs such as catuaba, damiana, epimedium, maca and muria puama for improving sexual activity in males, in addition to enhancing oral hygiene |
| 02/17/2005 | US20050036953 Topical compositions of ammonium lactate |
| 02/17/2005 | US20050036952 Compositions and methods for the treatment of aches and pains |
| 02/17/2005 | US20050036951 Methods of treating lung diseases |
| 02/17/2005 | US20050036949 A pharmaceutical dispenser; a liquid formulation comprising nitric oxide; respiratory system diseases; atomizing |
| 02/17/2005 | US20050036943 Methods and compositions for the diagnosis of asthma |
| 02/17/2005 | US20050036904 Chelation of calcium compound, demineralization; disinfecting; prevent kidney stones; atherosclerosis; administering antibiotics |
| 02/17/2005 | US20050035267 Furnace mount and method of installation |
| 02/17/2005 | US20050035266 Furnace Mount and Method of Installation |
| 02/17/2005 | US20050035177 Method for preparing colloidal solution of bismuth sodium tartrate |
| 02/17/2005 | US20050034652 Crystalline forms of modafinil |
| 02/17/2005 | DE10335027A1 Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis |
| 02/17/2005 | DE10334226A1 Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse Use of tyrosine kinase inhibitors for treating inflammatory processes |
| 02/17/2005 | DE10333509A1 New recognition molecules for the vascular endothelial growth factor gene, useful for treatment, diagnosis and monitoring of solid tumors and leukemia |
| 02/17/2005 | DE10333508A1 New recognition molecules for the prothrombin gene, useful for treatment, diagnosis and monitoring of thromboembolic disease, target a specific region in prothrombin mRNA |
| 02/17/2005 | DE10330213A1 Verwendung von Inhibitoren der Plasmamembran-Calcium-Atpase (PMCA) zur Hemmung der Spermienmobilität Use of inhibitors of plasma membrane calcium ATPase (PMCA) to inhibit sperm mobility |
| 02/17/2005 | DE10329812A1 Sustained release composition useful in the treatment of e.g. benign prostatic hyperplasia comprises Tamsulosin core with a coating containing combination of polyvinyl acetate and polyvinyl pyrrolidone |
| 02/17/2005 | CA2555323A1 Polypeptide specific to liver cancer, polynucleotide coding for the polypeptide, and rna molecule suppressing expression of the polypeptide |
| 02/17/2005 | CA2554566A1 Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
| 02/17/2005 | CA2539227A1 Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| 02/17/2005 | CA2537865A1 Neuroprotectin protects against cellular apoptosis, neuronal stroke damage, alzheimer's disease and retinal degeneration |
| 02/17/2005 | CA2536486A1 Steroid derivatives and use thereof as medicaments |
| 02/17/2005 | CA2535506A1 Pharmaceutical compositions for preventing breast and ovarian cancer |
| 02/17/2005 | CA2535448A1 Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions |
| 02/17/2005 | CA2535446A1 Methods for preventing neurological events |
| 02/17/2005 | CA2535403A1 Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases |
| 02/17/2005 | CA2535260A1 Method for treating cachexia with retinoid ligands |
| 02/17/2005 | CA2535249A1 Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
| 02/17/2005 | CA2535235A1 Topical composition comprising terbinafine and hydrocortisone |
| 02/17/2005 | CA2535125A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | CA2535098A1 Method for inhibiting bacterial colonisation |
| 02/17/2005 | CA2535066A1 Macrophage activation inhibitor |
| 02/17/2005 | CA2535029A1 Pharmaceutical compositions and methods for accelerating wound healing |
| 02/17/2005 | CA2535026A1 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 02/17/2005 | CA2534934A1 Advantageous combinations for inhalation of nacystelyn and bronchodilators |
| 02/17/2005 | CA2534909A1 P16 mediated regulation of nmda receptors |
| 02/17/2005 | CA2534905A1 Pyridyl piperazinyl ureas |
| 02/17/2005 | CA2534868A1 Compounds for the treatment of demyelinating and autoimmune diseases |
| 02/17/2005 | CA2534811A1 Quinazoline derivatives as angiogenesis inhibitors |
| 02/17/2005 | CA2534785A1 Tetrahydroquinazoline derivatives as cfr antagonists |
| 02/17/2005 | CA2534709A1 Polysaccharides derivatives with high antithrombotic activity in plasma |
| 02/17/2005 | CA2534693A1 Medicaments for inhalation comprising steroids and a betamimetic |
| 02/17/2005 | CA2534692A1 Parasiticidal composition |
| 02/17/2005 | CA2534675A1 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors |
| 02/17/2005 | CA2534670A1 Conjugated linolenic acids and methods of preparation and purification and uses thereof |
| 02/17/2005 | CA2534658A1 Trefoil factor 3 (tff3) as a target for anti-cancer therapy |
| 02/17/2005 | CA2534645A1 Composition and method for promoting hair growth |
| 02/17/2005 | CA2534528A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparationand use as modulators of apoptosis |
| 02/17/2005 | CA2534496A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | CA2534494A1 Pyrrole-based hmg-coa reductase inhibitors |
| 02/17/2005 | CA2534484A1 Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| 02/17/2005 | CA2534480A1 Novel composition comprising rosiglitazone and another antidiabetic agent |
| 02/17/2005 | CA2534422A1 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases |
| 02/17/2005 | CA2534415A1 Therapeutic delivery of carbon monoxide |
| 02/17/2005 | CA2534405A1 Halogenated quinazolinyl nitrofurans as antibacterial agents |
| 02/17/2005 | CA2534292A1 Substituted imidazopyrimidines for the prevention and treatment of cancer |
| 02/17/2005 | CA2534240A1 Treatment for alzheimer's disease and related conditions |
| 02/17/2005 | CA2534157A1 Viscosity-stable bismuth-containing pharmaceutical compositions |
| 02/17/2005 | CA2534136A1 Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/17/2005 | CA2534132A1 Medicaments for inhalation comprising betamimetics and an anticholinergic |
| 02/17/2005 | CA2534125A1 Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| 02/17/2005 | CA2534102A1 Use of spermine and/or spermidine against skin ageing in dietary, pharmaceutical or cosmetic compositions |
| 02/17/2005 | CA2534101A1 2-`4-(hydroxymethyl-phenylamino) -piperidine-1-yl!-n- (9h-carbazol-3-yl) - acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity |
| 02/17/2005 | CA2534100A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 02/17/2005 | CA2534099A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 02/17/2005 | CA2534098A1 Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/17/2005 | CA2534097A1 Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator |
| 02/17/2005 | CA2534096A1 2-`4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatement of obesity |
| 02/17/2005 | CA2534057A1 Novel gamma-secretase inhibitors |
| 02/17/2005 | CA2533996A1 1-sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands |
| 02/17/2005 | CA2533990A1 Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| 02/17/2005 | CA2533976A1 Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/17/2005 | CA2533970A1 Indol-6 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/17/2005 | CA2533861A1 Combinations comprising staurosporines |
| 02/17/2005 | CA2533786A1 Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| 02/17/2005 | CA2533464A1 Thiazole derivatives as npy antagonists |
| 02/17/2005 | CA2533463A1 2-amino-5-benzoylthiazole npy antagonists |
| 02/17/2005 | CA2533335A1 Substituted lactams and their use as anti-cancer agents |
| 02/17/2005 | CA2533329A1 New therapeutic use of chondroitin sulphate |
| 02/17/2005 | CA2533182A1 Dry syrup containing loratadine |
| 02/17/2005 | CA2533174A1 Novel dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof |
| 02/17/2005 | CA2533163A1 Novel compositions of sildenafil free base |
| 02/17/2005 | CA2532948A1 Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| 02/17/2005 | CA2532910A1 4,5-dihydro-imidazole as p2x7 ion channel blockers |
| 02/17/2005 | CA2532795A1 Sense antiviral compound and method for treating ssrna viral infection |
| 02/17/2005 | CA2532669A1 Semi-solid systems containing azetidine derivatives |